Oncogenic Mutants of MEK1 : A Trilogy Unfolds.

Autor:	Maust JD; Department of Pharmacology, Michigan Medicine, Ann Arbor, Michigan., Whitehead CE; Mekanistic Therapeutics, LLC, Ann Arbor, Michigan., Sebolt-Leopold JS; Department of Pharmacology, Michigan Medicine, Ann Arbor, Michigan. jssl@med.mich.edu.; Mekanistic Therapeutics, LLC, Ann Arbor, Michigan.; Department of Radiology, Michigan Medicine, Ann Arbor, Michigan.
Jazyk:	angličtina
Zdroj:	Cancer discovery [Cancer Discov] 2018 May; Vol. 8 (5), pp. 534-536.
DOI:	10.1158/2159-8290.CD-18-0192
Abstrakt:	It has generally been assumed that MEK mutants function similarly to one another and respond in the same manner to targeted drugs. Gao and colleagues challenge this assumption and report that MEK1 mutants fall into three unique phenotypic classes with respect to RAF dependency. A new class of MEK1 mutants is shown here to be RAF-independent, resistant to allosteric MEK inhibitors, and yet sensitive to treatment with a new ATP-competitive MEK inhibitor. Cancer Discov; 8(5); 534-6. ©2018 AACR See related article by Gao et al., p. 648 . (©2018 American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu